Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Dixie Esseltine
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Concepts & Ideas
Phenomena
Procedures
Physiology
Sign-in to see full Profile
Network (preview)
15
Anderson, Kenneth
13
Schenkein, David
12
Richardson, Paul
10
Barlogie, Bart
9
Irwin, David
9
Jagannath, Sundar
7
Orlowski, Robert
6
Rajkumar, Vincent
6
Singhal, Seema
6
Lonial, Sagar
6
Alexanian, Raymond
6
Alsina, Melissa
6
Boral, Anthony
6
Cavenagh, Jamie
6
Bladé, Joan
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Dixie Esseltine (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Richardson Paul G; Xie Wanling; Mitsiades Constantine; Chanan-Khan Asher A; Lonial Sagar; Hassoun Hani; Avigan David E; Oaklander Anne Louise; Kuter David J; Wen Patrick Y; Kesari Santosh; Briemberg Hannah R; Schlossman Robert L; Munshi Nikhil C; Heffner L Thompson; Doss Deborah; Esseltine Dixie-Lee; Weller Edie; Anderson Kenneth C; Amato Anthony A
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
-
2009: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Bladé Joan; Boccadoro Mario; Cavenagh Jamie D; Boral Anthony L; Esseltine Dixie-Lee; Wen Patrick Y; Amato Anthony A; Anderson Kenneth C; San Miguel Jesus
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
-
2008: Dees E Claire; O'Neil Bert H; Lindley Celeste M; Collichio Frances; Carey Lisa A; Collins Jason; Riordan William J; Ivanova Anastasia; Esseltine Dixie; Orlowski Robert Z
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):99-107.
-
2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
-
2008: Lonial Sagar; Richardson Paul G; San Miguel Jesús; Sonneveld Pieter; Schuster Michael W; Bladé Joan; Cavenagh Jamie; Rajkumar S Vincent; Jakubowiak Andrzej J; Esseltine Dixie-Lee; Anderson Kenneth C; Harousseau Jean-Luc
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
-
2008: Zangari Maurizio; Guerrero Jose; Cavallo Federica; Prasad H Keshava; Esseltine Dixie; Fink Louis
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Haematologica 2008;93(6):953-4.
-
2008: Popat Rakesh; Oakervee Heather E; Hallam Simon; Curry Nicola; Odeh Liz; Foot Nicola; Esseltine Dixie-Lee; Drake Mary; Morris Curly; Cavenagh Jamie D
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
British journal of haematology 2008;141(4):512-6.
-
2008: Mateos María-Victoria; Hernández José M; Hernández Miguel T; Gutiérrez Norma C; Palomera Luis; Fuertes Marta; Garcia-Sanchez Pedro; Lahuerta Juán J; de la Rubia Javier; Terol María-José; Sureda Ana; Bargay Joan; Ribas Paz; Alegre Adrian; de Arriba Felipe; Oriol Albert; Carrera Dolores; García-Laraña José; García-Sanz Ramón; Bladé Joan; Prósper Felipe; Mateo Gemma; Esseltine Dixie-Lee; van de Velde Helgi; San Miguel Jesús F
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Haematologica 2008;93(4):560-5.
-
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
-
2007: Zangari Maurizio; Esseltine Dixie; Cavallo Federica; Neuwirth Rachel; Elice Francesca; Burns Michael J; Yaccoby Shmuel; Richardson Paul; Sonneveld Pieter; Tricot Guido
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
American journal of hematology 2007;82(9):831-3.
-
2007: Viala Muriel; Bhakar Asha L; de la Loge Christine; van de Velde Helgi; Esseltine Dixie; Chang Mark; Dhawan Ravinder; Dubois Dominique
Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis.
Journal of clinical epidemiology 2007;60(7):670-679.
-
2007: Mulligan George; Mitsiades Constantine; Bryant Barb; Zhan Fenghuang; Chng Wee J; Roels Steven; Koenig Erik; Fergus Andrew; Huang Yongsheng; Richardson Paul; Trepicchio William L; Broyl Annemiek; Sonneveld Pieter; Shaughnessy John D; Bergsagel P Leif; Schenkein David; Esseltine Dixie-Lee; Boral Anthony; Anderson Kenneth C
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
-
2006: Sezer Orhan; Vesole David H; Singhal Seema; Richardson Paul; Stadtmauer Edward; Jakob Christian; Boral Anthony L; Esseltine Dixie-Lee; Mehta Jayesh
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(3):233-5.
-
2006: Mateos María-Victoria; Hernández José-M; Hernández Miguel-T; Gutiérrez Norma-C; Palomera Luis; Fuertes Marta; Díaz-Mediavilla Joaquín; Lahuerta Juan-J; de la Rubia Javier; Terol María-José; Sureda Ana; Bargay Joan; Ribas Paz; de Arriba Felipe; Alegre Adrian; Oriol Albert; Carrera Dolores; García-Laraña José; García-Sanz Ramón; Bladé Joan; Prósper Felipe; Mateo Gemma; Esseltine Dixie-Lee; van de Velde Helgi; San Miguel Jesús-F
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Blood 2006;108(7):2165-72.
-
2006: Zangari Maurizio; Yaccoby Shmuel; Cavallo Federica; Esseltine Dixie; Tricot Guido
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(2):109-14.
-
2006: Faderl Stefan; Rai Kanti; Gribben John; Byrd John C; Flinn Ian W; O'Brien Susan; Sheng Shihong; Esseltine Dixie-Lee; Keating Michael J
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cancer 2006;107(5):916-24.
-
2006: Gerecitano John; Goy Andre; Wright John; MacGregor-Cortelli Barbara; Neylon Ellen; Gonen Mithat; Esseltine Dixie; Boral Anthony; Schenkein David; Busam Klaus; Teruya-Feldstein Julie; Sachs Dana; O'Connor Owen A
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
British journal of haematology 2006;134(4):391-8.
-
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
-
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
-
2006: Stubblefield M D; Slovin S; MacGregor-Cortelli B; Muzzy J; Scher H; Wright J; Esseltine D; Schenkein D; O'Connor O A
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2006;18(5):410-8.
-
2006: Yang C H; Gonzalez-Angulo A M; Reuben J M; Booser D J; Pusztai L; Krishnamurthy S; Esseltine D; Stec J; Broglio K R; Islam R; Hortobagyi G N; Cristofanilli M
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):813-7.
-
2006: Dubois Dominique; Dhawan Ravinder; van de Velde Helgi; Esseltine Dixie; Gupta Sanjay; Viala Muriel; de la Loge Christine
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):976-82.
-
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
-
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
-
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
-
2005: Zangari Maurizio; Esseltine Dixie; Lee Choon-Kee; Barlogie Bart; Elice Francesca; Burns Michael J; Kang Seung-Hee; Yaccoby Shmuel; Najarian Kevin; Richardson Paul; Sonneveld Peter; Tricot Guido
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
British journal of haematology 2005;131(1):71-3.
-
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
-
2005: Oakervee Heather E; Popat Rakesh; Curry Nicola; Smith Pat; Morris Curly; Drake Mary; Agrawal Samir; Stec Jim; Schenkein David; Esseltine Dixie-Lee; Cavenagh Jamie D
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
British journal of haematology 2005;129(6):755-62.
-
2005: Orlowski Robert Z; Voorhees Peter M; Garcia Reynaldo A; Hall Melissa D; Kudrik Fred J; Allred Tammy; Johri Anandhi R; Jones Paul E; Ivanova Anastasia; Van Deventer Hendrik W; Gabriel Don A; Shea Thomas C; Mitchell Beverly S; Adams Julian; Esseltine Dixie-Lee; Trehu Elizabeth G; Green Marie; Lehman Mary Jo; Natoli Susan; Collins Jason M; Lindley Celeste M; Dees E Claire
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Blood 2005;105(8):3058-65.
-
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
-
2005: O'Connor Owen A; Wright John; Moskowitz Craig; Muzzy Jamie; MacGregor-Cortelli Barbara; Stubblefield Michael; Straus David; Portlock Carol; Hamlin Paul; Choi Elizabeth; Dumetrescu Otila; Esseltine Dixie; Trehu Elizabeth; Adams Julian; Schenkein David; Zelenetz Andrew D
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):676-84.
-
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
-
2004: Papandreou Christos N; Daliani Danai D; Nix Darrell; Yang Hong; Madden Timothy; Wang Xuemei; Pien Christine S; Millikan Randall E; Tu Shi-Ming; Pagliaro Lance; Kim Jeri; Adams Julian; Elliott Peter; Esseltine Dixie; Petrusich Alexandria; Dieringer Pauline; Perez Cherie; Logothetis Christopher J
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2108-21.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2002: Orlowski Robert Z; Stinchcombe Thomas E; Mitchell Beverly S; Shea Thomas C; Baldwin Albert S; Stahl Stephanie; Adams Julian; Esseltine Dixie-Lee; Elliott Peter J; Pien Christine S; Guerciolini Roberto; Anderson Jessica K; Depcik-Smith Natalie D; Bhagat Rita; Lehman Mary Jo; Novick Steven C; O'Connor Owen A; Soignet Steven L
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4420-7.
Sign-in to see more
